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The	 pituitary	 gland	 is	 a	 critical	 organ	 that	 is	 necessary	 for	many	 physiological	
processes,	 including	 growth,	 reproduction,	 and	 stress	 response.	 These	 vital	 processes	
are	 regulated	 through	 the	 secretion	of	pituitary	hormones	 from	specialized	cell	 types.	
Pituitary	hormone-producing	cells	arise	from	a	common	pool	of	pituitary	progenitors	in	
the	 developing	 Rathke’s	 pouch,	 and	 mutations	 that	 disrupt	 the	 formation	 and	
differentiation	 of	 pituitary	 progenitors	 often	 result	 in	 hypopituitarism,	 pituitary	
adenomas,	or	craniopharyngiomas.	Thus,	 it	 is	necessary	to	determine	the	mechanisms	
of	 pituitary	 development	 in	 order	 to	 understand	 the	 ways	 in	 which	 these	 congenital	
defects	 and	 tumors	 develop	 and	 disrupt	 pituitary	 function.	 Canonical	 WNT	 signaling	
through	 CTNNB1	 (β-CATENIN)	 is	 known	 to	 regulate	 the	 formation	 of	 the	 POU1F1	
lineage,	which	includes	somatotropes,	 lactotropes,	and	thyrotropes.	When	β-catenin	 is	
deleted	during	the	 initial	 formation	of	pituitary	progenitors,	Pou1f1	 is	not	 transcribed,	
leading	 to	 the	 loss	 of	 the	 POU1F1	 lineage.	 However,	 when	β-catenin	 is	 deleted	 after	
lineage	 specification,	 there	 is	 no	 observable	 effect.	 Similarly,	 the	 generation	 of	 a	 β-
catenin	gain-of-function	allele	 in	early	pituitary	progenitors	or	stem	cells	results	 in	the	
formation	 of	 craniopharyngiomas,	 while	 stimulating	 β-CATENIN	 in	 differentiated	 cell	
types	has	no	effect.	To	date,	previous	studies	have	not	determined	the	role	of	canonical	




to	 lineage	 specification.	We	 utilized	 the	 Prop1-cre	 to	 conduct	 both	 loss-	 and	 gain-of-
function	 studies	 on	 β-CATENIN	 during	 this	 critical	 window	 in	 pituitary	 gland	
development.	Our	results	demonstrate	that	pituitary	progenitors	remain	sensitive	to	β-
CATENIN	at	this	time	point.	Deletion	of	β-catenin	during	this	critical	window	resulted	in	
loss	 of	 the	 POU1F1	 lineage,	 as	 expected,	 as	 well	 as	 an	 increase	 in	 the	 expression	 of	
TBX19	(TPIT),	with	a	subsequent	increase	in	the	corticotrope	population.	Stimulating	β-











































physiological	 processes,	 such	 as	 growth	 and	 development,	 stress	 management,	
reproduction,	 and	 metabolism.	 The	 pituitary	 gland	 is	 often	 called	 the	 master	 gland	
because	of	its	role	in	regulating	the	functions	of	the	other	endocrine	glands	through	the	
secretion	 of	 hormones	 from	 specialized	 hormone	 cell	 types.	 In	 humans,	 the	 pituitary	
gland	 is	 composed	 of	 two	 distinct	 lobes:	 the	 anterior	 lobe,	 also	 known	 as	 the	
adenohypophysis,	 and	 the	 posterior	 lobe,	 or	 neurohypophysis.	 The	 anterior	 lobe	
originates	 from	an	 invagination	of	 the	oral	ectoderm,	under	 the	direction	of	BMP	and	
FGF	signaling	from	the	neural	ectoderm	of	the	ventral	diencephalon	(1).		
This	preliminary	pituitary	gland,	called	Rathke’s	pouch,	is	composed	of	pituitary	
progenitor	 cells,	 which	 then	 undergo	 cell	 specification	 and	 differentiation	 in	
coordination	with	cell	cycle	exit	and	intrinsic	signaling	factors.	From	this	common	pool	
of	 pituitary	 progenitors,	 cells	 begin	 to	 differentiate	 through	 one	 of	 three	 distinct	 cell	




adrenocorticotropic	 hormone	 (ACTH)	 and	 melanotropes,	 which	 secrete	 melanocyte-
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stimulating	 hormone	 (MSH)	 (3).	 The	 gonadotropes,	 which	 secrete	 follicle-stimulating	
hormone	(FSH)	and	luteinizing	hormone	(LH),	express	NR5A1	(SF1)	and	αGSU	(4).	
To	date,	research	on	pituitary	cell	specification	and	differentiation	has	yielded	a	
transcription	 factor	 hierarchy	 that	 originates	 with	 PITX1	 and	 LHX3	 marking	 potential	
pituitary	 progenitors	 within	 the	 oral	 ectoderm	 at	 e8.5	 (5,6).	 Rathke’s	 pouch,	 under	
direction	from	the	ventral	diencephalon,	begins	to	invaginate	from	the	oral	ectoderm	at	
e9.5,	 and	 at	 this	 time,	 pituitary	 progenitors	 begin	 to	 express	 HESX1	 (7).	 By	 e11.5,	
Rathke’s	 pouch	 is	 completely	 closed	 off	 from	 the	 oral	 ectoderm	and	 the	 proliferating	
progenitors	 around	 its	 lumen	 express	 PROP1	 (8,9).	 From	 this	 pool	 of	 PROP1-positive	
progenitors,	we	generate	all	hormone-producing	cell	types,	along	with	a	population	of	
pituitary	 stem	 cells,	 which	 can	 be	 activated	 to	 undergo	 differentiation	 later	 in	 life	 as	
needed,	such	as	during	puberty	or	times	of	prolonged	stress	(10).		
A	 greater	 understanding	 of	 pituitary	 gland	 development	 will	 help	 us	 to	
determine	 how	 mutations	 develop	 and	 disrupt	 pituitary	 function.	 Mutations	 during	
pituitary	 development	 most	 often	 result	 in	 hypopituitarism,	 pituitary	 adenomas,	 or	
craniopharyngiomas.	Combined	pituitary	hormone	deficiency	(CPHD)	is	a	common	form	
of	 hypopituitarism	 that	 involves	 impaired	 production	 of	 growth	 hormone	 and	 one	 or	
more	other	pituitary	hormones	(11).	Pituitary	adenomas	arise	from	mutations	in	specific	
hormone-producing	 cell	 types,	 leading	 to	 an	 excess	 secretion	 of	 that	 particular	
hormone.	Acromegaly	is	a	prime	example	of	a	pituitary	adenoma	wherein	an	excess	of	
growth	 hormone	 is	 secreted,	 leading	 to	 bone	 overgrowth,	 significant	 morbidity,	 and	
increased	mortality	 (12).	Adamantinomatous	craniopharyngiomas	 (ACPs)	are	unique	 in	
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that	they	arise	from	pituitary	progenitors	or	stem	cells	and	are	not	associated	with	an	




Many	 instances	 of	 hypopituitarism	 or	 pituitary	 tumor	 formation	 have	 been	
linked	to	mutations	in	key	transcription	factors.	Mutations	in	PROP1	or	POU1F1	are	the	






β-CATENIN	 expression	 after	 cell	 specification	 has	 occurred	 does	 not	 result	 in	 any	
observable	 pituitary	 defects	 (15,16).	 Previous	 studies	 have	 not	 yet	 determined	 if	 β-
CATENIN	plays	a	role	in	pituitary	development	in-between	these	two	critical	timepoints:	
after	pituitary	progenitor	 formation,	 but	before	 cell	 specification.	Here,	we	utilize	 the	





Pituitary	 gland	 organogenesis	 is	 a	 complex	 process	 involving	 coordination	
between	both	 intrinsic	and	extrinsic	signals.	Previous	studies	 in	mice	have	shown	that	
the	pituitary	 gland	 is	 derived	 from	 two	ectodermal	 regions	 in	 close	proximity	 to	 each	
other:	the	neural	ectoderm	of	the	ventral	diencephalon	and	the	surface	ectoderm	of	the	
oral	 epithelium	 (5).	 The	 ventral	 diencephalon	 evaginates	 to	 form	 an	 infundibulum,	
which	gives	 rise	 to	 the	posterior	 lobe	of	 the	adult	pituitary.	The	anterior	 lobe,	on	 the	
other	hand,	is	derived	from	an	invagination	of	the	oral	ectoderm,	called	Rathke’s	pouch.	
In	 mice,	 Rathke’s	 pouch	 also	 forms	 an	 intermediate	 lobe,	 which	 houses	 the	
melanotropes	in	the	adult	pituitary	gland	(3).	These	two	ectodermal	structures	are	vital	
not	only	 for	the	 initial	 formation	of	the	preliminary	pituitary,	but	also	for	the	extrinsic	
signals	 that	 regulate	 the	 size	 and	 shape	 of	 the	 forming	 pituitary	 gland.	 BMP	 and	 FGF	
signaling	 factors	 in	 the	 ventral	 diencephalon	 are	 called	 the	 pituitary	 organizer,	 in	
reference	to	their	role	in	regulating	pituitary	gland	induction	and	growth	(17).	
Bone	morphogenic	protein	4	 (BMP4)	 is	expressed	 in	 the	 infundibular	 region	of	
the	 ventral	 diencephalon	 and	 is	 responsible	 for	 initiating	 the	 invagination	 of	 Rathke’s	
pouch	 from	 the	 oral	 ectoderm,	 as	 indicated	 by	 the	 failure	 of	Bmp4-/-	mice	 to	 form	 a	
viable	Rathke’s	pouch	at	e9.5	 (18).	 Fibroblast	 growth	 factors	8	 (FGF8)	and	10	 (FGF10)	
are	expressed	in	an	overlapping	expression	pattern	with	BMP4	and	are	responsible	for	
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promoting	 proliferation	 in	 the	 forming	 Rathke’s	 pouch	 (1,19).	 Sonic	 hedgehog	 (SHH)	
expression	is	located	rostral	and	ventral	to	the	regions	of	BMP	and	FGF	expression	in	the	
ventral	 diencephalon	 and	 acts	 in	 opposition	 to	 these	 signaling	 factors,	 resulting	 in	





restrict	 the	 expansion	 of	 BMPs	 and	 FGFs	 in	 the	 ventral	 diencephalon,	 as	 deletion	 of	








(23).	 Other	 oral	 ectoderm	 transcription	 factors,	 including	 PITX1	 and	 PITX2,	 are	





and	PITX2	also	 leads	 to	 a	 failure	 to	express	 LHX3,	 another	early	pituitary	marker	 [Fig.	
2.1]	 (24).	 Lhx3-/-	 embryos	 are	 lacking	 the	 anterior	 and	 intermediate	 lobes	 of	 the	
pituitary,	a	direct	effect	of	its	role	in	the	proliferation	of	cells	in	Rathke’s	pouch	(6,25).	
HESX1,	 a	 transcription	 factor	 primarily	 involved	 in	 anterior	 forebrain	 development,	




gland	 development.	 Its	 expression	 begins	 at	 e10.5,	 corresponding	 with	 a	 down-
regulation	 of	 HESX1	 in	 pituitary	 progenitors	 (5,8).	 PROP1	 is	 expressed	 in	 all	 pituitary	
progenitors	 at	 e11.5,	 as	 these	 proliferating	 cells	 begin	 to	 exit	 the	 cell	 cycle	 [Fig.	 2.1]	
(9,27).	Early	pituitary	progenitors	in	Rathke’s	pouch	express	markers	of	proliferation	and	
growth,	 including	 Ki67,	 SOX2,	 CCND1,	 and	 CCND2,	 as	well	 as	markers	 of	 an	 epithelial	
tissue	 state,	 such	 as	 E-CADHERIN	 (28,29).	 Upon	 cell	 cycle	 exit,	 pituitary	 progenitors	




and	 express	 transitional	markers,	 including	 p57Kip2,	 SOX2,	 and	 SOX9	 (28,29).	 PROP1	 is	
essential	 for	 progression	 through	 EPT	 and	 directly	 regulates	 the	 expression	 of	 factors	
required	for	EPT,	including	ZEB2,	GLI2,	MMP2,	MMP3,	and	MMP16	(30,31).	
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Starting	 around	 e13.5,	 this	 PROP1-positive	 population	 of	 cells	 begins	 to	
differentiate	into	the	hormone-producing	cell	types	of	the	anterior	pituitary.	PROP1,	in	
conjunction	 with	 β-CATENIN,	 is	 directly	 responsible	 for	 the	 transcription	 of	 POU1F1,	
through	 suppression	 of	 HESX1	 expression	 and	 binding	 to	 the	 POU1F1	 promoter	 to	
activate	transcription	[Fig.	2.1]	 (15,32).	Prop1df/df	mice,	also	referred	to	as	Ames	dwarf	
mice,	 have	 severely	 reduced	 numbers	 of	 somatotropes,	 lactotropes,	 and	 thyrotropes,	
consistent	 with	 a	 significant	 decrease	 in	 cells	 expressing	 POU1F1	 (31,33).	 In	 human	
patients	with	 PROP1	mutations,	 anterior	 pituitary	 function	 deteriorates	 progressively,	
and	 includes	 adrenal	 insufficiency	 in	 addition	 to	 deficiencies	 in	 GH,	 TSH,	 and	 the	
gonadotropins	 (34).	 As	 expected,	 Pou1f1dw/dw	 mice,	 or	 Snell	 dwarf	 mice,	 have	
hypoplastic	 anterior	 pituitaries	 in	 combination	with	 deficiencies	 in	 all	 POU1F1	 lineage	




Proopiomelanocortin	 (POMC)	begins	 to	be	expressed	around	e13.5	 in	Rathke’s	
pouch	and	marks	developing	corticotropes	and	melanotropes	(35).	TBX19	and	PITX1	act	
as	 co-activators	of	 POMC	gene	 transcription,	 and	human	mutations	 in	Tbx19	 result	 in	
isolated	 ACTH	 deficiency	 [Fig.	 2.1]	 (3,35).	 NEUROD1	 is	 also	 important	 for	 the	
development	 of	 the	 POMC-derived	 cell	 types,	 but	 is	 more	 specifically	 involved	 in	
corticotrope	development	 (36).	ACTH-positive	corticotropes	are	normally	expressed	as	
early	 as	 e13.5	 in	 wild-type	 embryos;	 however,	 in	 Neurod1-/-	 embryos,	 corticotrope	
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differentiation	 is	 delayed	 (36).	 This	 delay	 is	 transient	 and	 ACTH	 expression	 recovers	
completely	 by	 e16.5,	 suggesting	 that	 NEUROD1	 is	 required	 for	 the	 correct	 timing	 of	
corticotrope	differentiation	(36).	TBX19	is	also	 important	for	repressing	the	expression	
of	 other	 lineage-specific	 transcription	 factors,	 such	 as	 POU1F1	 and	 SF1,	 as	 seen	 in		
Tbx19-/-	 embryos,	 which	 generate	 gonadotropes	 and	 thyrotropes	 in	 the	 developing	
intermediate	lobe	instead	of	the	usual	melanotropes	(35).	HES1,	a	downstream	effector	
of	 NOTCH	 signaling,	 is	 similarly	 involved	 in	 regulating	 the	 different	 cell	 specification	
pathways,	 as	 Hes1-/-	 embryos	 contain	 somatotropes	 instead	 of	 melanotropes	 in	 the	
intermediate	 lobe	 (37).	 This	 suggests	a	possible	antagonistic	 relationship	between	 the	
three	 cell	 specification	 pathways,	 to	 regulate	 formation	 versus	 repression	 of	 the	
different	hormone-producing	cell	types.	
Potential	gonadotropes	begin	to	express	steroidogenic	factor	1	(SF1)	at	e13.5,	an	
orphan	 nuclear	 receptor	 involved	 in	multiple	 levels	 of	 the	 reproductive	 axis	 [Fig.	 2.1]	
(38).	Outside	of	the	pituitary	gland,	SF1	regulates	the	enzymes	that	produce	sex	steroids	
in	 the	 adrenal	 glands,	 testes,	 and	 ovaries	 (4).	Within	 anterior	 pituitary	 gonadotropes,	
SF1	directly	regulates	the	expression	of	LHβ,	FSHβ,	and	αGSU,	the	alpha-subunit	partner	








anterior	 pituitary	 hormones	 detectable	 prior	 to	 birth	 [Fig.	 2.1].	 The	 one	 exception	 is	
prolactin,	 which	 is	 not	 detectable	 via	 immunostaining	 in	 lactotropes	 until	 after	 birth	
(40).	 These	 fully	 differentiated	 hormone-producing	 cells	 of	 the	 anterior	 lobe	 now	




robust	and	coordinated	 response	of	 these	cells	 to	hormone-releasing	signals	 from	the	





PROP1-positive,	 SOX2-positive	 pituitary	 progenitors	 as	 the	 rest	 of	 the	 cells	 in	 the	
anterior	and	intermediate	lobes;	however,	they	become	quiescent	and	do	not	undergo	
an	 EPT	 (29).	 These	 quiescent	 cells	 express	 common	 markers	 of	 stem	 cells,	 including	
SOX2,	 SOX9,	 OCT4,	 and	 E-CADHERIN,	 along	 with	 other	 transcription	 factors	 and	
receptors,	 such	as	PROP1	and	GFRα2	 (10,29).	Pituitary	 stem	cells	are	able	 to	undergo	
differentiation	 later	 in	 life,	 particularly	 when	 the	 demand	 for	 a	 specific	 hormone	 is	
greater	 than	 the	 anterior	 pituitary	 can	manage	 (43).	 Two	 prime	 examples	 of	 this	 are	







hypopituitarism	 in	 the	United	 States	 (45).	 Combined	 pituitary	 hormone	 deficiency,	 or	





OTX2,	 SOX2,	 SOX3,	 SF1,	 and	 TBX19	 (26,35,38,46,47).	 Despite	 the	 fact	 that	 so	 many	
members	of	the	transcription	factor	hierarchy	are	included	in	this	list,	 less	than	half	of	
all	 known	 causes	 of	 congenital	 hypopituitarism	 have	 been	 attributed	 to	 one	 of	 these	
transcription	factors	(46).	Currently,	the	only	available	treatment	for	hypopituitarism	is	
hormonal	 replacement	 therapy,	which	 is	 not	 ideal	 because	medications	 cannot	mimic	




Craniopharyngiomas	 are	 intracranial	 tumors	 that	 arise	 from	 mutations	 in	 the	
pituitary	 stem	 cell	 population	 (51).	 There	 are	 two	 subtypes	 of	 craniopharyngiomas:	
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papillary	 (PCP)	 and	 adamantinomatous	 (ACP);	 of	 these,	 ACPs	 are	 the	 most	 common,	
accounting	for	up	to	10%	of	pediatric	intracranial	tumors	(51,52).	ACPs	are	characterized	
histologically	 by	 collections	 of	 whorl-like	 nodules	 consisting	 of	 cytokeratin-enriched	
abnormal	epithelium	 (51).	 These	epithelial-like	 cell	 clusters	most	 closely	 resemble	 the	
nodules	 of	 other	 epithelial	 stem	 cell	 derived	 tumors,	 including	 basal	 cell	 carcinomas,	
pilomatricomas,	 etc	 (53,54).	 Although	 craniopharyngiomas	 are	 histologically	 benign,	




the	 surrounding	 tissues	 (56).	 A	 better	 understanding	 of	 the	 molecular	 pathways	
involved	in	ACP	development	may	help	us	identify	novel	therapeutic	targets.	Canonical	
WNT	 signaling	 through	 β-CATENIN	 has	 been	 identified	 as	 a	 major	 player	 in	 ACP	
formation,	 as	 approximately	 95%	 of	 ACP	 tumors	 contain	 activating	 mutations	 in	 β-
catenin	(51,52).	
There	are	multiple	WNT	signaling	 transduction	pathways,	 categorized	as	either	
canonical	or	non-canonical,	based	on	whether	 the	signal	 is	mediated	by	 the	canonical	
WNT	factor,	β-CATENIN	(57).	Both	canonical	and	non-canonical	WNT	pathways	 involve	







This	 complex	 binds	 and	 ubiquitinates	 β-CATENIN	 in	 the	 cytoplasm,	 targeting	 it	 for	
degradation	 by	 proteasomes	 (57).	 However,	 when	 a	 WNT	 ligand	 binds	 to	 its	 FZD	
receptor	 and	 activates	 a	 canonical	 signaling	 cascade,	 the	APC/GSK3β/AXIN	 complex	 is	
inhibited,	allowing	β-CATENIN	 to	accumulate	 in	 the	cytoplasm,	enter	 the	nucleus,	and	
regulate	transcription	of	various	target	genes	(57).	β-CATENIN	is	most	commonly	a	co-
activator	 or	 co-repressor	 of	 transcription	 in	 conjunction	 with	 another	 transcription	
factor,	 primarily	 those	 of	 the	 TCF/LEF	 family	 (62).	 In	 addition	 to	 being	 a	mediator	 of	
canonical	WNT	signaling	through	its	interactions	with	β-CATENIN,	LEF1	is	also	a	target	of	
canonical	 WNT	 signaling	 in	 a	 β-CATENIN-dependent,	 LEF-independent	 manner	 (62).	
TCF/LEF	factors	are	considered	to	be	the	ubiquitous	transcription-regulating	partners	of	
β-CATENIN;	 however,	 β-CATENIN	 can	 also	 interact	 with	 other	 tissue-specific	
transcription	factors	(57).	A	prime	example	of	this	is	PROP1,	which,	as	we	have	already	
discussed,	 acts	 in	 conjunction	 with	 β-CATENIN	 to	 activate	 POU1F1	 transcription	 (15).	
Another	relevant	example	is	the	ability	of	β-CATENIN	to	convert	PITX2	from	a	repressor	
to	an	activator	in	order	to	regulate	cell	proliferation	(63).	PITX2	is	required	for	CCND2,	
CCND1,	and	c-MYC	expression,	all	of	which	are	G1	cell	 cycle	 control	 genes;	 therefore,	
through	its	interaction	with	PITX2,	β-CATENIN	is	able	to	regulate	the	expression	of	these	
three	genes	(64).	
Canonical	WNT	 signaling	 is	 important	 for	many	different	 aspects	 of	 embryonic	
development,	 including	 progenitor	 formation,	 cell	 specification	 and	 differentiation,	
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stem	 cell	 regulation,	 and	 EMT	 (65,66).	 Previous	 studies	 have	 identified	 many	 WNT	
signaling	factors	within	Rathke’s	pouch	and	have	begun	to	determine	the	roles	they	play	
in	pituitary	gland	development	(67).	To	date,	canonical	WNT	signaling	has	been	shown	










catenin	 in	 early	 pituitary	 progenitors	 results	 in	 the	 loss	 of	 the	 POU1F1	 lineage	 (15).	
However,	 deleting	 β-catenin	 after	 cell	 specification,	 using	 the	 Pou1f1-cre,	 does	 not	
result	 in	 any	 observable	 pituitary	 defect	 (15).	 Other	 experiments	 have	 sought	 to	
determine	 the	 effect	 of	 stimulating	 canonical	 WNT	 signaling	 on	 pituitary	 gland	
development.	Conditional	deletion	of	β-CATENIN	exon	3	results	in	an	activated	form	of	
β-CATENIN	which	cannot	be	ubiquitinated	and	degraded,	even	in	the	absence	of	a	WNT	
ligand	 (70).	 Using	 this	 gain-of-function	 (GOF)	 allele	 in	 combination	 with	 either	 the	
Hesx1-cre	 or	 the	 Sox2-cre,	 it	 was	 determined	 that	 stimulating	 β-CATENIN	 in	 early	
pituitary	 progenitors	 results	 in	 an	 ACP-like	 nuclear	 accumulation	 of	 β-CATENIN,	
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formation	of	whorled	 clusters	of	 β-CATENIN-positive	 cells,	 and	an	overall	 hyperplastic	
pituitary	gland	 (16).	Similar	 to	 the	conditional	deletion	experiments,	 there	 is	no	effect	
on	the	pituitary	gland	when	stimulating	β-CATENIN	after	cell	specification	has	occurred,	
using	a	Pou1f1-cre,	Gh-cre,	or	Prl-cre	(16).	
To	 date,	 no	 experiments	 have	 been	 conducted	 to	 determine	 the	 role	 of	 β-
CATENIN	in-between	these	two	major	time	points:	after	pituitary	progenitor	formation	
but	 prior	 to	 cell	 specification.	 None	 of	 the	 aforementioned	 cre	 recombinases	 are	
expressed	 in	 the	 correct	 temporal	 and	 spatial	 location	 to	 allow	 us	 to	 conduct	 these	
experiments.	Thus,	we	will	use	the	recently	developed	Prop1-cre	to	determine	the	effect	
of	deleting	β-CATENIN	in-between	these	two	key	time	points	in	pituitary	development.	
The	 Prop1-cre	 is	 pituitary-specific,	 unlike	 other	 early	 pituitary	 markers,	 and	 is	 active	
beginning	at	e11.5,	after	the	initial	formation	of	pituitary	progenitors,	with	the	peak	of	
its	expression	occurring	during	EPT,	prior	to	lineage	specification	at	e13.5	(9).	Using	the	
Prop1-cre	 will	 allow	 us	 to	 conditionally	 delete	 or	 activate	 β-CATENIN	 solely	 within	
Rathke’s	pouch	and	at	 the	correct	 timing	 in	pituitary	development	so	as	 to	determine	












South	 Carolina	 approved	 all	 experiments	 using	mice.	 The	 Ctnnb1tm2Kem	 (β-catfx/fx)	 and	
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo	 	 (RosamTmG)	 mice	 were	 obtained	 from	 Jackson	
Laboratory	(71).	Ctnnb1tm1Mmt	(β-catGOF)	mice	were	obtained	from	Mark	Taketo	at	Kyoto	
University	 via	 Santhakumar	 Manicassamy	 of	 Augusta	 University	 (70).	 Prop1-cre	 mice	
were	generated	at	the	University	of	Michigan	and	are	available	from	the	Mutant	Mouse	
Resource	 and	 Research	 Center	 at	 the	 University	 of	 North	 Carolina	 at	 Chapel	 Hill	 (9).	
Mice	were	fed	without	restriction	and	housed	in	specific	pathogen	free	conditions	with	
automatic	 watering.	 Genotyping	 of	 mice	 was	 performed	 as	 previously	 reported	
(9,70,71).	 The	 observation	 of	 a	 copulation	 plug	 was	 used	 to	 initiate	 the	 timing	 of	
embryonic	 development;	 noon	 on	 the	 day	 the	 copulation	 was	 observed	 was	 then	
defined	 as	 e0.5.	 Sexual	 dimorphism	 of	 the	 pituitary	 gland	 is	 not	 observed	 until	 after	
birth,	 therefore,	 tissues	were	 chosen	 for	 experiments	without	 regard	 for	 sex	 (72).	 All	
experiments	 were	 conducted	 using	 at	 least	 four	 mutant	 embryos.	 Embryos	 with	 the	
genotype	 Prop1-cre;	 β-catfx/fx,	 for	 loss-of-function	 studies,	 or	 Prop1-cre;	 β-catGOF,	 for	
gain-of-function	 studies,	 were	 designated	 as	 mutant	 embryos	 for	 their	 respective	
studies.	 All	 other	 embryonic	 genotypes	 generated	 in	 the	 same	 litter	 as	 the	 mutant	
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embryos	 were	 designated	 as	 wild-type	 embryos	 as	 all	 displayed	 a	 normal,	 healthy	
pituitary	phenotype.	
Histology,	Immunostaining,	&	RNAscope	
Embryos	 at	 appropriate	 developmental	 time	 points	 were	 collected	 and	 fixed	
overnight	 in	4%	paraformaldehyde	 in	phosphate	buffered	saline	 (PBS)	at	4°C	 (73).	The	
fixative	 was	 removed	 and	 the	 embryos	 were	 washed	 in	 PBS,	 dehydrated	 into	 100%	




and	 dilutions.	 All	 immunostaining	 experiments,	 except	 for	 pituitary	 hormone	
immunostaining,	were	 boiled	 in	 10	mM	 citric	 acid,	 pH	 6.0	 for	 10	minutes	 to	 retrieve	
epitopes.	Experiments	utilizing	horseradish	peroxidase	 (HRP)	 for	 signal	detection	were	
incubated	 in	 50%	 Methanol	 and	 1.5%	 Hydrogen	 Peroxide	 for	 20	 minutes	 at	 room	




(TSA)	 kit	 #22	 dissolved	 in	 PBS	 (Thermo	 Fisher	 Scientific).	 Primary	 antibodies	 were	






were	 either	 followed	 by	 SIGMAFAST	 3,3’-Diaminobenzidine	 (DAB)	 staining	 (Sigma)	 or	
TSA	 with	 Alexa	 Fluor	 488	 (TSA	 Kit	 #22,	 Thermo	 Fisher	 Scientific)	 for	 3	 minutes.	
Fluorescent	 detection	 methods	 were	 counterstained	 with	 300	 nM	 4',6-diamidino-2-
phenylindole	 (DAPI)	 for	 5	minutes	 before	mounting	 in	 fluorescence	mounting	media,	
while	 DAB	 detection	 was	 counterstained	 with	 0.5%	 Methyl	 Green	 in	 0.1	 M	 Sodium	




In	 situ	 detection	 of	 β-CATENIN	mRNA	using	 the	 RNAscope	 2.5	HD	 reagent	 kit-	
BROWN	 (Advanced	 Cell	 Diagnostics)	 was	 performed	 according	 to	 manufacturer’s	
recommendations	and	as	previously	 reported	on	tissue	sections	cut	at	6	μm	thickness	
(17).	Both	positive	and	negative	probes	supplied	by	the	manufacturer	were	tested	on	all	
tissues	 used	 for	 RNAscope.	 Tissues	 were	 counterstained	 with	 a	 50%	 hematoxylin	
solution.	
Quantification	Experiments	
	 To	determine	 the	proportion	of	 total	 cells	 expressing	POU1F1	or	 SF1	 at	 e14.5,	





determine	 the	 total	 number	 of	 cells.	 Dividing	 the	 total	 number	 of	 POU1F1-	 or	 SF1-
positive	cells	by	the	number	of	DAPI-stained	nuclei	produced	the	proportion	of	POU1F1-	
or	 SF1-positive	 cells	 for	 each	 embryo.	 The	 proportion	 of	 TBX19-positive	 cells	 was	
similarly	determined,	with	the	exception	that	the	proportion	of	TBX19-positive	cells	to	
DAPI-stained	 nuclei	 was	 also	 determined	 in	 the	 intermediate	 lobe	 to	 differentiate	
between	 anterior	 lobe	 corticotropes	 and	 intermediate	 lobe	 melanotropes.	 The	
proportion	 of	 hormone	 positive	 cells	 for	 four	 wild-type	 and	 four	 Prop1-cre;	 β-catfx/fx	
mutant	embryos	was	determined	using	images	of	coronal	sections	at	e18.5	as	above.	
	 The	periluminal	epithelium	of	Rathke’s	pouch	is	composed	of	columnar	cells	in	a	
pseudostratified	 epithelium.	 These	 cells	 are	 morphologically	 distinct	 from	 the	
epithelioid	 cells	 of	 the	pituitary	 parenchyma	 in	 the	 anterior	 lobe.	 	 This	morphological	
distinction	was	used	to	select	a	region	of	interest	containing	the	periluminal	epithelium	
on	 images	of	H&E	 stained	wild-type	and	Prop1-cre;	β-catGOF	mutant	embryos,	 and	 the	
area	of	the	region	of	interest	was	determined	using	ImageJ.	For	each	of	four	wild-type	
and	four	Prop1-cre;	β-catGOF	mutant	embryos,	five	sections	distributed	across	the	left	to	
right	 axis	 of	 the	 pituitary	 gland	were	 selected	 and	 the	 area	 of	 periluminal	 epithelium	
was	 determined	 for	 each	 section	 along	 with	 an	 overall	 average	 area	 of	 periluminal	
epithelium	for	each	embryo.			
	 To	 determine	 differences	 in	 expression	 of	 SOX9	 at	 e14.5	 in	 high	 and	 low	 β-
CATENIN	 expression	 regions	 of	 Prop1-cre;	 β-catGOF	mutant	 embryos,	 β-CATENIN	 and	
SOX9	 double-immunostained	 images	 were	 analyzed	 in	 ImageJ.	 Regions	 of	 high	 β-
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CATENIN	 expression	 were	 used	 to	 determine	 regions	 of	 interest,	 and	 within	 these	
regions	 the	 total	 number	of	 SOX9-positive	 cells	 and	 the	 total	 number	of	DAPI-stained	
nuclei	were	used	to	generate	a	proportion	of	SOX9-positive	cells.	Periluminal	epithelial	
cells	with	 low	β-CATENIN	expression	were	used	 to	determine	 regions	of	 interest	with	
low	 β-CATENIN	 expression,	 and	 the	 proportion	 of	 SOX9-positive	 cells	 was	 also	
determined	within	these	regions	of	 interest.	Single	 images	 from	four	 individual	Prop1-
cre;	β-catGOF	mutant	embryos	were	analyzed.			
	 To	 determine	 differences	 in	 CCND2	 expression	 at	 e16.5	 between	 the	
intermediate	 lobes	 of	 wild-type	 embryos	 and	 regions	 with	 high	 and	 low	 β-CATENIN	
expression	 in	 Prop1-cre;	 β-catGOF	mutant	 embryos,	 the	 proportion	 of	 CCND2-positive	
cells	 was	 determined	 as	 above	 in	 each	 region.	 For	 wild-type	 embryos,	 single	 images	
from	 four	 embryos	 were	 analyzed.	 For	 Prop1-cre;	 β-catGOF	 mutant	 embryos,	 three	
images	from	each	of	four	mutant	embryos	were	analyzed.	In	Prop1-cre;	β-catGOF	mutant	
embryos,	the	regions	of	high	β-CATENIN	expression	where	separated	into	large	clusters,	






































































































































































































Since	 canonical	WNT	signaling	 is	dependent	on	 the	nuclear	accumulation	of	β-
CATENIN,	we	sought	to	inhibit	canonical	WNT	signaling	in	pituitary	progenitors	using	a	
conditional	null	approach.	The	Ctnnb1tm2Kem	(β-catfx)	allele	has	loxP	sites	flanking	exons	2	
through	 6	 and	 results	 in	 a	 null	 allele	 in	 the	 presence	 of	 a	 cre	 recombinase	 (71).	 As	
previously	mentioned,	the	Prop1-cre	mediates	cre	recombination	beginning	at	e11.5	in	
the	 pituitary	 progenitors	 of	 Rathke’s	 pouch	 (9).	 We	 crossed	 Prop1-cre;	 β-catfx/+	 mice	




also	 present	 at	 adherens	 junctions	 and	 can	 persist	 at	 the	membrane	 for	many	 hours	
following	 cre-mediated	 deletion	 (77).	 To	 determine	 the	 exact	 timing	 of	 β-CATENIN	
protein	deletion	in	Rathke’s	pouch,	we	performed	an	immunostaining	for	β-CATENIN	at	
various	 embryonic	 time	 points	 [Fig.	 4.1].	 At	 e12.5,	 e14.5,	 and	 e18.5,	 β-CATENIN	 is	
detectable	 throughout	 Rathke’s	 pouch	 in	 wild-type	 embryos,	 and	 its	 expression	 is	
concentrated	 primarily	 at	 the	 cell	 membrane	 [Fig.	 4.1A,C,E].	 In	 Prop1-cre;	 β-catfx/fx	
mutant	embryos,	small	patches	of	cells	in	Rathke’s	pouch	are	deficient	in	β-CATENIN	at	
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CD31	 (PECAM)	 and	 are	 not	 derived	 from	 the	 population	 of	 PROP1-positive	 pituitary	
progenitors	(78).	
Because	β-CATENIN	protein	expression	persists	after	cre	recombination,	we	also	
assayed	 β-catenin	 mRNA	 expression	 using	 RNAscope,	 a	 highly-sensitive	 in-situ	
hybridization	technique	that	has	been	previously	used	in	the	pituitary	gland	(17,79).	At	
e12.5	in	wild-type	embryos,	β-catenin	mRNA	is	detectable	in	the	epithelium	of	Rathke’s	
pouch;	 however,	 in	 the	 forming	 anterior	 lobe,	 β-catenin	 transcription	 is	 drastically	
reduced	[Fig.	4.1I].	This	pattern	of	β-catenin	expression	is	maintained	in	e14.5	wild-type	




catenin	mRNA	expression	 is	 reduced	but	not	absent	at	e12.5	and	 is	not	detectable	at	
e14.5	 [Fig.	 4.1J,L].	 These	 results	 suggest	 that	 the	 Prop1-cre	 successfully	 mediates	




the	 deletion	 of	 the	 β-catfx/fx	 locus	 even	 when	 β-CATENIN	 protein	 persists	 at	 the	 cell	
membrane	(77).	Because	LEF1	is	a	transcriptional	target	of	canonical	WNT	signaling,	we	
assayed	 LEF1	 expression	 in	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	 to	 determine	 if	




but	 is	 still	 not	 observed	 in	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	 [Fig.	 4.1O,P].	 These	






CATENIN,	 POU1F1	 expression	 should	 be	 significantly	 reduced	 in	 Prop1-cre;	 β-catfx/fx	
mutant	embryos.	As	expected,	POU1F1	expression	is	almost	absent	in	the	anterior	lobe	








intermediate	 and	 anterior	 lobes	 to	 distinguish	 between	 the	 intermediate	 lobe	
melanotropes	 and	 the	 anterior	 lobe	 corticotropes.	 The	mean	 proportion	 of	 each	 cell	
type	 from	 four	 individuals	 of	 each	 genotype	was	 compared	using	 a	 two-sample	 t-test	
with	 unequal	 variance.	 As	 expected	 from	 a	 visual	 inspection	 of	 the	 immunostained	
images,	 POU1F1	 was	 significantly	 reduced	 in	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	
compared	 to	 wild-type	 (P	 =	 0.014).	 TBX19	 expression	 has	 previously	 been	 shown	 to	
increase	 when	 β-catenin	 is	 deleted	 in	 early	 pituitary	 progenitors	 (15);	 therefore,	 we	
expected	 to	 see	 an	 increase	 in	 the	 proportion	of	 TBX19-positive	 cells	 in	Prop1-cre;	 β-
catfx/fx	 mutant	 embryos	 compared	 to	 wild-type.	 In	 the	 anterior	 lobe,	 the	 mean	




embryos	 compared	 to	wild-type	 (P	 =	 0.014).	 By	 e18.5,	 POU1F1	expression	 appears	 to	






factors,	 we	 examined	 the	 expression	 of	 pituitary	 hormones	 in	 Prop1-cre;	 β-catfx/fx	
mutant	 embryos	 to	 see	 if	 any	 of	 the	 hormones	 were	 likewise	 affected	 [Fig.	 4.3].	 As	
expected,	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	 at	 e18.5	 have	 reduced	 numbers	 of	
somatotropes	 and	 thyrotropes,	 increased	 numbers	 of	 corticotropes,	 and	 similar	





of	POMC-positive	cells	 in	 the	anterior	 lobe	was	significantly	 increased	(P	=	0.021)	 [Fig.	
4.3I].	 Collectively,	 the	 results	 from	 Figures	 4.2	 and	 4.3	 demonstrate	 that	 pituitary	
progenitors	 are	 sensitive	 to	 the	 loss	 of	 canonical	 WNT	 signaling	 during	 the	 period	
following	induction	of	Rathke’s	pouch	and	before	cell	lineage	commitment.	
We	 hypothesized	 that	 the	 low	 proportion	 of	 POU1F1-positive	 cells	 in	 the	
anterior	 lobe	 results	 from	 persistent	 β-CATENIN	 protein	 following	 cre-mediated	
recombination.	We	 immunostained	wild-type	embryos	and	Prop1-cre;	β-catfx/fx	mutant	
embryos	 at	 e14.5	 for	 both	 β-CATENIN	 and	 POU1F1	 to	 determine	 whether	 POU1F1-
positive	 cells	 have	persistent	 β-CATENIN	expression	 [Fig.	 4.4A-H].	 In	mutant	 embryos,	
POU1F1-positive	 cells	 maintained	 β-CATENIN	 expression	 at	 the	 plasma	 membrane,	
indicating	that	these	cells	do	not	have	a	complete	loss	of	β-CATENIN.	
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We	 then	 assayed	 the	 efficiency	 of	 β-catenin	 recombination	 by	 generating	 β-
catfx/fx	mice	 that	 also	 carry	 a	 cre	 reporter	 construct,	RosamTmG	 (81).	 This	 ubiquitously-
expressed,	 double-fluorescent	 reporter	 expresses	 the	 membrane-targeted	 tdTomato	
(mT)	prior	to	cre	recombination	and	the	membrane-targeted	green	fluorescent	protein	
(mG)	 after	 excision,	 allowing	 us	 to	 visualize	 cre	 activity	 (81).	 β-catfx/fx;	 RosamTmG/mTmG	
mice	 were	 crossed	 with	 Prop1-cre;	 β-catfx/+	 mice	 to	 generate	 Prop1-cre;	 β-catfx/fx;	
RosamTmG/+	mutant	embryos	and	wild-type	littermates.	We	used	expression	of	enhanced	
green	 florescent	 protein	 (eGFP)	 from	 the	 recombined	 RosamTmG	 locus	 to	 visualize	




small	patches	of	eGFP-negative	 cells	 in	 the	anterior	 lobe,	demonstrating	 that	 in	 these	
mutant	 embryos,	 some	 pituitary	 progenitors	 are	 able	 to	 escape	 recombination	
mediated	 by	 the	 Prop1-cre	 [Fig.	 4.4M-P].	 Immunostaining	 for	 both	 GFP	 and	 POU1F1	
shows	 that	POU1F1	 is	expressed	 in	 these	patches	of	eGFP-negative	cells	 [Fig.	4.4N-P].	




the	 transcription	of	 POU1F1	 (15).	 This	 same	 study	 also	 showed	 that	 LEF1	 inhibits	 this	
transcriptional	activation	of	POU1F1	by	PROP1/	β-CATENIN	in	a	transiently	transfected	
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pituitary	 cell	 line	 (15).	 Given	 the	 negative	 regulation	 of	 POU1F1	 by	 LEF1,	 we	 would	
expect	 that	 LEF1-positive	 cells	 in	 the	 anterior	 lobe	 would	 not	 express	 POU1F1.	 We	
performed	double	immunostaining	for	POU1F1	and	LEF1	on	wild-type	embryos	at	e14.5	
and	 found	 that	our	expectation	was	 incorrect;	POU1F1-positive	cells	 can	express	 LEF1	
[Fig.	 4.4Q-T].	 Not	 all	 POU1F1-positive	 cells	 are	 LEF1-positive,	 but	 most	 LEF1-positive	
cells	 express	 POU1F1.	 Therefore,	 LEF1	 can	 be	 used	 as	 an	 indicator	 of	 canonical	WNT	
signaling	 activity	 in	 POU1F1-positive	 cells.	 Having	 established	 this	 association,	 we	
examined	 the	 occurrence	 of	 POU1F1/LEF1	 double-positive	 cells	 in	Prop1-cre;	 β-catfx/fx	
mutant	embryos	and	 found	 that	 the	sparse	POU1F1-positive	cells	also	expressed	LEF1	
[Fig.	4.4U-X].	This	result	indicates	that	canonical	WNT	signaling	is	still	active	in	these	few	
POU1F1-positive	cells	 in	 the	anterior	 lobe	of	Prop1-cre;	β-catfx/fx	mutant	embryos,	and	
likely	 results	 from	 the	presence	of	pituitary	progenitor	 cells	 that	did	not	undergo	cre-
mediated	recombination	of	the	β-catenin	locus.	
We	know	that	PROP1	is	required	for	POU1F1	transcription,	but	the	relationship	
between	 PROP1	 and	 the	 other	 two	 lineage-specific	 factors	 is	 largely	 unknown	 (15).	
Based	 on	 the	 known	 relationship	 between	 PROP1	 and	 POU1F1,	 we	 performed	
PROP1/POU1F1	 double	 immunostaining	 on	 e14.5	 wild-type	 embryos	 to	 determine	 if	
their	 expression	 patterns	 overlapped	 in	 the	 developing	 anterior	 lobe	 [Fig.	 4.5A-D].	 As	
expected,	these	two	transcription	factors	appear	in	three	different	expression	patterns	
in	 the	 cells	 of	 the	 anterior	 lobe:	 cells	 that	 are	 only	 positive	 for	 PROP1,	 cells	 that	 are	
positive	for	both	PROP1	and	POU1F1,	and	cells	 that	are	only	positive	for	POU1F1	[Fig.	
4.5B-D].	 These	 results	 suggest	 a	 gradual	 conversion	 between	 the	 proliferating	
	31	








wild-type	 embryos	 and	 determined	 that	 TBX19	 and	 SF1	 do	 not	 have	 overlapping	




	 Previous	 studies	 have	 suggested	 a	 possible	 antagonistic	 relationship	 between	
the	three	cell	specification	pathways	in	the	developing	anterior	lobe	(35,37).	Our	results	
demonstrate	 that	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	 have	 decreased	 expression	 of	
POU1F1	 and	 two	 of	 its	 lineage	 cell	 types,	 somatotropes	 and	 thyrotropes,	 and	 a	
corresponding	 increase	 in	 the	expression	of	 TBX19	and	SF1,	 along	with	an	 increase	 in	
corticotropes.	This	decrease	in	cells	from	one	cell	specification	pathway	accompanied	by	
a	funneling	of	cells	toward	the	other	two	cell	specification	pathways	suggests	that	the	
three	 cell	 specification	 pathways	 are	 maintained	 in	 a	 relative	 balance	 by	 some	
regulatory	mechanism.	 In	order	 to	explore	this	 further,	we	determined	the	number	of	
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DAPI-positive	 nuclei	 in	 the	 anterior	 lobe	 of	 midsagittal	 sections	 from	 four	 individual	
e14.5	 pituitaries	 for	 each	 genotype.	 The	 total	 number	 of	 anterior	 pituitary	 cells	 in	






results	 in	 pituitary	 dysmorphology	 and	 ACP	 formation	 (16,43).	 This	 is	 in	 contrast	 to	
stimulating	canonical	WNT	signaling	at	e14.5	or	later,	which	has	no	observed	effect	on	
pituitary	morphology	 (16).	We	used	 the	Prop1-cre	 and	 the	β-catGOF	 allele	 to	 stimulate	
canonical	WNT	 signaling	 beginning	 at	 e11.5.	 Histological	 examination	 of	 e16.5	Prop1-
cre;	 β-catGOF	 mutant	 embryos	 compared	 with	 wild-type	 indicates	 that	 stimulating	
canonical	WNT	signaling	at	this	time	point	also	results	in	highly	dysmorphic	pituitaries,	
demonstrating	 that	 pituitary	 progenitors	 at	 e11.5	 have	 not	 become	 refractory	 to	
canonical	WNT	signaling	[Fig.	4.6Aa-Ab].	
	 β-CATENIN	 immunostaining	 at	 e16.5	 indicates	 an	 increase	 in	 β-CATENIN	
accumulation	in	Prop1-cre;	β-catGOF	mutant	embryos	compared	with	wild-type	embryos	
[Fig.	 4.6Ac-Ad].	 Despite	 the	 fact	 that	 the	 Prop1-cre	 is	 expressed	 in	 all	 pituitary	
progenitors,	 this	 increased	 accumulation	of	 β-CATENIN	 is	 not	 observed	 in	 all	 pituitary	




of	 cre	 expression	 and	 generation	 of	 the	 β-catGOF	 allele	 (16,43).	 Our	 results,	 in	




catGOF	 mutant	 embryos,	 we	 performed	 β-CATENIN	 immunostaining	 on	 wild-type	 and	
mutant	embryos	at	e12.5	and	e14.5	[Fig.	4.6Ba-Bd].	At	e12.5,	small	foci	of	increased	β-
CATENIN	 expression	were	 observed	 in	Prop1-cre;	 β-catGOF	mutant	 embryos.	 By	 e14.5,	
we	begin	to	see	a	highly	dysmorphic	pituitary	phenotype	accompanied	by	an	increase	in	
the	 periluminal	 epithelial	 tissue	 and	 bulging	 regions	 that	 express	 high	 levels	 of	 β-
CATENIN.	 A	 similar	 pattern	 occurs	 with	 LEF1	 expression,	 where	 small	 foci	 of	 LEF1-
positive	cells	were	observed	in	Prop1-cre;	β-catGOF	mutant	embryos	at	e12.5,	while	LEF1	
is	 completely	 absent	 in	 wild-type	 embryos	 at	 this	 time	 [Fig.	 4.6Be-Bf].	 These	 ectopic	
domains	 of	 LEF1	 expression	 resemble	 developing	 foci	 in	 the	 Hesx1-cre;	 β-catGOF	 and	
Sox2creERT2;	β-catGOF	models	of	ACP	(16,43).	At	e14.5,	LEF1	expression	mirrors	that	of	β-
CATENIN	 and	 is	 expressed	 in	 the	 same	 clusters	 of	 cells	 that	 are	 bulging	 out	 from	 the	
periluminal	 epithelium,	 indicating	 that	 canonical	 WNT	 signaling	 is	 increased	 in	 these	





appears	 expanded	 compared	 to	 wild-type,	 we	 determined	 the	 average	 area	 of	
periluminal	epithelial	 tissue	from	five	sagittal	sections	across	the	 lateral	 to	medial	axis	
for	 four	 wild-type	 and	 four	 mutant	 embryos	 at	 e14.5,	 when	 the	 dysmorphology	
becomes	 clearly	 apparent	 [Fig.	 4.6C].	A	 representative	 region	of	 periluminal	 epithelial	
tissue	 is	 outlined	 in	 Figure	 4.6Bc	 and	 Bd.	Wild-type	 embryos	 had	 a	mean	 periluminal	
epithelial	area	of	27.5	±	4.6	mm2,	whereas	Prop1-cre;	β-catGOF	mutant	embryos	had	a	
mean	periluminal	epithelial	area	of	118.7	±	15.0	mm2,	which	is	a	statistically	significant	







POU1F1,	 TBX19,	 and	 SF1	 –	 were	 also	 not	 expressed	 in	 any	 pituitary	 tissues	 of	 e18.5	
Prop1-cre;	β-catGOF	mutant	embryos	[Fig.	4.8A-F].	
At	 e14.5	 in	 wild-type	 embryos,	 PROP1	 is	 expressed	 in	 pituitary	 progenitors	






4.8I],	 and	 its	 expression	 is	 dependent	 on	 PROP1	 (75).	 In	 Prop1-cre;	 β-catGOF	 mutant	
embryos,	NOTCH2	 is	 also	 expressed	 in	 the	 thin	 periluminal	 epithelium	and	not	 in	 the	
bulging	periluminal	 regions	 [Fig.	4.8J].	We	hypothesized	 that	high	 levels	of	β-CATENIN	







procedure	 [Fig.	 4.6Ac-Ad].	 Using	 these	 immunostaining	 conditions	 for	 β-CATENIN	 in	
combination	 with	 PROP1	 immunostaining,	 we	 confirmed	 that	 PROP1	 is	 expressed	 in	
pituitary	epithelial	cells	that	do	not	accumulate	high	levels	of	β-CATENIN	[Fig.	4.9C-E].	
Because	 these	 high	 β-CATENIN	 cell	 clusters	 do	 not	 express	 PROP1,	 lineage	
specification	factors,	or	pituitary	hormones,	it	 is	possible	that	these	cells	are	stuck	in	a	
pituitary	progenitor/stem	cell	 stage.	 To	determine	whether	 these	high	β-CATENIN	cell	
clusters	 represent	pituitary	 stem	cells,	we	performed	double	 immunostainings	 for	 the	







we	determined	the	proportion	of	SOX9-positive	cells	 in	each	region	for	 four	 individual	
Prop1-cre;	β-catGOF	mutant	embryos	[Fig.	4.9U].	The	mean	proportion	in	high	β-CATENIN	
cell	clusters	was	0.128	±	0.039,	which	 is	significantly	 less	than	the	mean	proportion	of	
0.602	 ±	 0.165	 in	 the	 remaining	 periluminal	 epithelium	 (two-sample	 t-test	 assuming	
unequal	variances,	P	=	0.008)	[Fig.	4.9U].	These	results	suggest	that	the	high	β-CATENIN	
cell	clusters	do	not	have	a	pituitary	identity,	as	they	do	not	express	early,	intermediate,	
or	 definitive	 markers	 of	 pituitary	 cell	 types,	 with	 the	 exception	 of	 SOX9,	 which	 has	
sharply	reduced	expression.	
We	next	set	out	to	determine	if	these	Prop1-cre;	β-catGOF	dysmorphic	pituitaries	
resembled	ACPs	as	have	already	been	 shown	 in	Hesx1-cre;	β-catGOF	 and	Sox2creERT2;	β-
catGOF	 mice.	 Knowing	 that	 ACPs	 are	 slow-growing	 tumors	 characterized	 by	 a	 low	
proliferative	 index,	we	used	Ki67	to	 identify	actively	cycling	cells	and	found	that	e14.5	
Prop1-cre;	 β-catGOF	 mutant	 embryos	 do	 not	 express	 Ki67	 in	 the	 bulging	 cell	 clusters	
typical	 of	 high	 β-CATENIN	 expression	 [Fig.	 4.10Aa-Ab],	 demonstrating	 that	 these	 cell	
clusters	 are	 proliferating	 slowly.	 Ki67	was	 expressed	 in	 the	 thin	 periluminal	 epithelial	
tissue	 characterized	 by	 low	 β-CATENIN	 expression,	 similar	 to	 its	 expression	 in	 the	
epithelial	tissue	around	the	lumen	of	wild-type	embryos.	
CCND2	(CYCLIN	D2)	is	necessary	for	the	transition	form	G1	to	S	and	can	be	used	
as	 an	 indicator	 of	 proliferative	 cells.	 β-CATENIN	 is	 known	 to	 regulate	 CCND2	
transcription	 through	 an	 interaction	 with	 PITX2,	 and	 CCND2	 has	 been	 used	 as	 an	
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indicator	 of	 canonical	WNT	 signaling	 activity,	 similar	 to	 LEF1	 (64).	 At	 e16.5,	 CCND2	 is	
primarily	expressed	in	the	epithelial	 layer	around	the	lumen	in	wild-type	embryos	[Fig.	
4.10Ac].	In	Prop1-cre;	β-catGOF	mutant	embryos,	CCND2	is	expressed	in	both	the	high	β-






and	 four	Prop1-cre;	β-catGOF	mutant	embryos	 for	CCND2	at	e16.5	and	determined	 the	
mean	proportion	of	CCND2-expressing	cells	 in	 four	different	 regions:	 the	 intermediate	
lobe	 epithelium	 of	 wild-type	 embryos,	 the	 epithelial	 regions	 with	 low	 β-CATENIN	 in	
Prop1-cre;	 β-catGOF	 mutant	 embryos,	 the	 large	 cell	 clusters	 with	 high	 β-CATENIN	 in	
mutant	embryos,	and	the	small	cell	clusters	with	high	β-CATENIN	in	mutant	embryos.	An	
one-way	ANOVA	comparison	of	 the	mean	proportion	of	CCND2-positive	 cells	 in	 these	
four	 groupings	 showed	 that	 there	was	 a	 significant	 difference	between	 the	 groupings	
(F(3,	 12)	 =	20.5,	 P	 =	5.12	×	 10-5).	A	post	hoc	 t-test	between	wild-type	epithelium	and	
mutant	low	β-CATENIN-expressing	epithelium	was	not	significantly	different,	suggesting	
that	these	two	regions	are	equivalent	(two-sample	t-test	assuming	unequal	variances,	P	




t-test	 assuming	 unequal	 variances,	 P	 =	 0.002)	 were	 significantly	 different,	 suggesting	
that	 CCND2	 is	 up-regulated	 in	 the	 small,	 high	 β-CATENIN	 cell	 clusters	 and	 down-
regulated	in	the	large,	high	β-CATENIN	cell	clusters	[Fig.	4.10B].	Our	analysis	of	Ki67	and	
CCND2	 expression	 patterns	 indicates	 that	 large,	 high	 β-CATENIN	 cell	 clusters	 have	 a	
reduced	proliferative	capacity.	
ACP	tumors	from	Hesx1-cre;	β-catGOF	mice	are	characterized	by	the	expression	of	
CK8	 and	 CK18,	which	 are	 indicative	 of	 an	 oral	 ectoderm	 identity	 (16).	We	 performed	
immunostaining	 in	wild-type	 and	Prop1-cre;	 β-catGOF	mutant	 embryos	 at	 18.5	with	 an	
antibody	 that	 recognizes	 both	 CK8	 and	 CK18,	 in	 combination	 with	 β-CATENIN	
immunostaining	to	 identify	regions	of	high	β-CATENIN	expression	[Fig.	4.10Ca-Cb].	We	
observed	 CK8/18	 expression	 throughout	 the	 pituitary	 gland	 of	 wild-type	 embryos,	
demonstrating	that	this	epithelial	marker	does	not	discriminate	between	the	epithelium	
of	the	intermediate	lobe	and	the	parenchyma	of	the	anterior	lobe.	CK8/18	is	expressed	
in	Prop1-cre;	β-catGOF	mutant	embryos	 in	 the	epithelia	outside	of	 the	high	β-CATENIN	
cell	 clusters,	 which	 is	 similar	 to	 its	 expression	 in	 wild-type	 embryos.	 This	 pattern	
resembles	that	of	other	pituitary	markers,	which	are	not	expressed	in	regions	with	high	
β-CATENIN	expression.		
Sox2creERT2;	 β-catGOF	 mice	 also	 form	 ACP	 tumors	 where	 cell	 foci	 with	 high	 β-
CATENIN	 expression	 express	 signaling	 factors,	 including	 SHH	 (43).	 Because	 SHH	 is	




[Fig.	4.10Cc-Cd]	and	observed	 that	SHH	 is	expressed	 in	 the	 regions	of	high	β-CATENIN	
expression	 in	 mutant	 embryos.	 Although	 SHH	 is	 not	 a	 definitive	 marker	 for	 oral	







and	 e18.5	 coronal	 sections	 [E-F],	 counterstained	with	DAPI	 (blue).	 [A,	 C,	 E]	Wild-Type	
and	[B,	D,	F]	Prop1-cre;	β-catfx/fx.	Dotted	 line	 in	 [A]	 indicates	Rathke’s	pouch.	Arrow	 in	
[B]	indicates	a	small	domain	with	no	β-CATENIN	expression.		Dotted	line	in	[E]	indicates	
the	pituitary	anterior	and	intermediate	lobes.	[G-H]	β-CATENIN	(green)	and	CD31	(red)	
double	 immunostaining	 on	 e18.5	 coronal	 sections,	 counterstained	 with	 DAPI	 (blue).	
White	dotted	 line	 indicates	anterior	 lobe;	 red	dotted	 line	 indicates	 intermediate	 lobe.	
[G]	Wild-Type	and	[H]	Prop1-cre;	β-catfx/fx.	Arrow	in	[H]	indicates	an	endothelial	cell	with	
β-CATENIN	 expression.	 Cells	 with	 bright	 green	 signal	 in	 [G]	 are	 autofluorescent	 red	
blood	 cells.	 [I-L]	 β-catenin	 RNAscope	 (brown)	 on	 e12.5	 [I-J]	 and	 e14.5	 [K-L]	 sagittal	
sections,	 counterstained	with	 hematoxylin	 (blue).	 [I,	 K]	Wild-Type.	 [J,	 L]	Prop1-cre;	 β-
catfx/fx.	 Arrow	 in	 [I]	 indicates	 a	 region	 of	 the	 developing	 anterior	 lobe	 with	 low	
expression	of	β-catenin	 [M-P]	 LEF1	 immunostaining	 (green),	 counterstained	with	DAPI	

























hormone	 cell	 type	 in	 wild-type	 and	 Prop1-cre;	 β-catfx/fx	 embryos	 at	 e18.5.	 Error	 bars	

















CATENIN	 expression.	 [I-P]	 POU1F1	 [red	 and	 J,	 N]	 and	 GFP	 [green	 and	 K,	 O]	 double	
immunostaining	 on	 e14.5	 coronal	 sections.	 [I-L]	 Wild-type	 (Prop1-cre;	 β-catfx/+;	
RosamTmG/+)	 and	 [M-P]	 Prop1-cre;	 β-catfx/fx;	 RosamTmG/+.	 [J-L]	 are	 higher	 magnification	
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images	of	the	boxed	region	in	[I],	and	[L]	is	an	overlay	of	individual	gray	scale	channels	
presented	 in	 [J-K].	 White	 arrows	 in	 [J-L]	 highlight	 the	 same	 cell	 in	 each	 panel	 with	
POU1F1	and	GFP	expression.	[N-P]	are	higher	magnification	images	of	the	boxed	region	
in	[M],	and	[P]	is	an	overlay	of	individual	gray	scale	channels	presented	in	[N-O].	White	
arrows	 in	 [N-P]	 highlight	 the	 same	 cell	 in	 each	 panel	 with	 POU1F1,	 but	 lacking	 GFP	
expression,	suggesting	an	absence	of	Prop1-cre	mediated	recombination.	[Q-X]	POU1F1	
[red	 and	 R,	 V]	 and	 LEF1	 [green	 and	 S,	 W]	 double	 immunostaining	 on	 e14.5	 sagittal	
sections.	 [Q-T]	Wild-type	 and	 [U-X]	Prop1-cre;	 β-catfx/fx.	 [R-T]	 are	higher	magnification	
images	of	the	boxed	region	in	[Q],	and	[T]	is	an	overlay	of	individual	gray	scale	channels	










[A-D]	PROP1	 [green	and	B]	 and	POU1F1	 [red	and	C]	double	 immunostaining	on	e14.5	
sagittal	sections.	[B-D]	are	higher	magnification	images	of	the	boxed	region	in	[A],	and	
[D]	 is	 the	overlay	of	 individual	gray	scale	channels	presented	 in	[B-C].	White	arrows	 in	
[B-D]	highlight	 the	 same	cell	 in	 each	panel	with	PROP1	and	POU1F1	expression.	 [E-H]	
PROP1	 [green	and	F]	and	TBX19	 [red	and	G]	double	 immunostaining	on	e14.5	 sagittal	
sections.	[F-H]	are	higher	magnification	images	of	the	boxed	region	in	[E],	and	[H]	is	the	
overlay	 of	 individual	 gray	 scale	 channels	 presented	 in	 [F-G].	 White	 arrows	 in	 [F-H]	
highlight	 the	 same	 cell	 in	 each	 panel	 with	 TBX19,	 but	 lacking	 PROP1	 expression,	
suggesting	that	PROP1	is	not	expressed	in	cells	that	express	TBX19.	[I-L]	SF1	[green	and	
J]	 and	 TBX19	 [red	 and	 K]	 double	 immunostaining	 on	 e14.5	 sagittal	 sections.	 [J-L]	 are	
higher	magnification	images	of	the	boxed	region	in	[I],	and	[L]	is	the	overlay	of	individual	
gray	 scale	 channels	presented	 in	 [J-K].	White	arrows	 in	 [J-L]	highlight	 the	 same	cell	 in	
each	 panel	 with	 TBX19,	 but	 lacking	 SF1	 expression,	 suggesting	 that	 TBX19	 is	 not	
expressed	in	cells	that	express	SF1.	All	scale	bars	equal	100	µm.	[M]	Graph	of	the	total	








[Aa-Ab]	 H&E	 staining	 of	 wild-type	 [Aa]	 and	 Prop1-cre;	 β-catGOF/+	 [Ab]	 e16.5	 coronal	
sections.	[Ac-Ad]	β-CATENIN	immunostaining	(green)	on	wild-type	[Ac]	and	Prop1-cre;	β-
catGOF/+	[Ad]	e16.5	coronal	sections,	counterstained	with	DAPI	(blue).	[Ba-Bb]	β-CATENIN	
immunostaining	 (red)	 on	 wild-type	 [Ba]	 and	 Prop1-cre;	 β-catGOF/+	 [Bb]	 e12.5	 sagittal	
sections,	 counterstained	 with	 DAPI	 (blue).	 Arrow	 in	 [Bb]	 indicates	 a	 small	 focus	 of	
increased	 β-CATENIN	 expression,	 in	 contrast	 to	 the	 uniform	 level	 of	 β-CATENIN	
expression	 observed	 in	 [Ba].	 [Bc-Bd]	 β-CATENIN	 immunostaining	 (green)	 on	wild-type	
[Bc]	 and	 Prop1-cre;	 β-catGOF/+	 [Bd]	 e14.5	 sagittal	 sections,	 counterstained	 with	 DAPI.	
Dotted	 lines	 in	 [Bc-Bd]	 indicate	 examples	 of	 periluminal	 epithelium	 used	 for	 area	
measurements	 in	 [C].	 [Be-Bh]	 LEF1	 immunostaining	 (red)	 on	 wild-type	 [Be,	 Bg]	 and	
Prop1-cre;	 β-catGOF/+	 [Bf,	 Bh]	 e12.5	 [Be-Bf]	 and	 e14.5	 [Bg-Bh]	 sagittal	 sections,	
counterstained	with	DAPI	 (blue).	 Arrow	 in	 [Bf]	 indicates	 a	 small	 focus	 of	 ectopic	 LEF1	
expression,	 in	contrast	to	the	 lack	of	LEF1	expression	 in	[Be].	Scale	bars	equal	100	µm	


















[A-F]	 Immunostaining	 for	 lineage	 specific	 transcription	 factors	 (red)	 on	 e16.5	 coronal	
sections,	 counterstained	 with	 DAPI	 (blue).	 [A,	 C,	 E]	 Wild-type	 embryos	 and	 [B,	 D,	 F]	
Prop1-cre;	 β-catGOF/+	 embryos	 immunostained	 for	 [A,	 B]	 TBX19,	 [C,	 D]	 SF1,	 and	 [E,	 F]	
POU1F1.	 [G-J]	 Immunostaining	 on	 e14.5	 sagittal	 sections	 of	 [G,	 I]	wild-type	 and	 [H,	 J]	
Prop1-cre;	β-catGOF/+	embryos,	counterstained	with	DAPI	(blue).	 [G-H]	PROP1	(red)	and	
[I-J]	 NOTCH2	 (green).	 Arrow	 in	 [H]	 indicates	 a	 region	 of	 periluminal	 epithelium	 with	
PROP1	 expression.	 Arrow	 in	 [I]	 indicates	 NOTCH2	 expression	 in	 wild-type	 periluminal	








[A]	 PROP1	 immunostaining	 (red)	 on	 a	wild-type	 e14.5	 sagittal	 section,	 counterstained	
with	 DAPI	 (blue).	 [B-E]	 PROP1	 [red	 and	 C]	 and	 β-CATENIN	 [green	 and	 D]	 double	
immunostaining	 on	 an	 e14.5	 Prop1-cre;	 β-catGOF/+	 sagittal	 section.	 [C-E]	 are	 higher	
magnification	images	of	the	boxed	region	in	[B],	and	[E]	is	the	overlay	of	individual	gray	
scale	channels	presented	in	[C-D].	[F]	LHX3	immunostaining	(green)	on	a	wild-type	e14.5	
sagittal	 section,	 counterstained	 with	 DAPI	 (blue).	 [G-J]	 LHX3	 [green	 and	 H]	 and	 β-
CATENIN	 [red	 and	 I]	 double	 immunostaining	 on	 a	 Prop1-cre;	 β-catGOF/+	e14.5	 sagittal	
section.	[H-J]	are	higher	magnification	images	of	the	boxed	region	in	[G],	and	[J]	 is	the	
overlay	of	 individual	gray	 scale	channels	presented	 in	 [H-I].	 	 [K]	SOX2	 immunostaining	
(red)	on	a	wild-type	e16.5	coronal	section,	counterstained	with	DAPI	(blue).	[L-O]	SOX2	
[red	and	M]	and	β-CATENIN	 [green	and	N]	double	 immunostaining	on	a	Prop1-cre;	β-
catGOF/+	 e16.5	 coronal	 section.	 [M-O]	 are	 higher	 magnification	 images	 of	 the	 boxed	
region	in	[L],	and	[O]	is	the	overlay	of	individual	gray	scale	channels	presented	in	[M-N].	
[P]	 SOX9	 immunostaining	 (red)	 on	 a	 wild-type	 e14.5	 sagittal	 section,	 counterstained	
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with	 DAPI	 (blue).	 [Q-T]	 SOX9	 [red	 and	 R]	 and	 β-CATENIN	 [green	 and	 S]	 double	
immunostaining	 on	 a	 Prop1-cre;	 β-catGOF/+	 e14.5	 sagittal	 section.	 [R-T]	 are	 higher	
magnification	images	of	the	boxed	region	in	[Q],	and	[T]	is	the	overlay	of	individual	gray	
scale	 channels	 presented	 in	 [R-S].	 	 The	 red	 dotted	 line	 in	 [T]	 indicates	 a	 periluminal	
region	 with	 low	 β-CATENIN	 expression,	 while	 the	 yellow	 dotted	 line	 represents	 a	
periluminal	region	with	high	β-CATENIN	expression.	These	regions	are	examples	of	areas	
used	to	determine	the	proportion	of	SOX9-expressing	cells	 in	 low	and	high	β-CATENIN	
expressing	 regions.	 [B,	G,	 L,	Q]	 Blue	 staining	 represents	DAPI	 counterstain.	 Scale	 bars	
equal	100	µm	for	all	images.	[U]	Graph	of	the	proportion	of	SOX9	expressing	cells	in	low	









[Aa-Ab]	 Ki67	 immunostaining	 (red)	 on	 e14.5	 wild-type	 [Aa]	 and	 Prop1-cre;	 β-catGOF/+	
[Ab]	 sagittal	 sections,	 counterstained	 with	 DAPI	 (blue).	 Arrow	 in	 [Ab]	 indicates	
proliferating	 cells	 in	 the	 periluminal	 epithelium,	 typically	 characterized	 by	 low	 β-
CATENIN	 expression.	 [Ac-Ad]	 CCND2	 (red)	 and	 β-CATENIN	 (green)	 double	
immunostaining	on	e16.5	wild-type	[Ac]	and	Prop1-cre;	β-catGOF/+	[Ad]	coronal	sections,	





small	 cell	 cluster	 with	 high	 β-CATENIN	 expression.	 [B]	 Graph	 of	 the	 proportion	 of	
CCND2-expressing	 cells	 in	 the	 wild-type	 intermediate	 lobe	 and	 Prop1-cre;	 β-catGOF/+	
periluminal	epithelium.	Error	bars	represent	the	standard	deviation;	asterisks	indicate	p	
<	 0.05	 in	 a	 two-sample	 t-test	 with	 unequal	 variance.	 [Ca-Cb]	 CK8+18	 (green)	 and	 β-
CATENIN	(red)	double	immunostaining	on	e18.5	wild-type	[Ca]	and	Prop1-cre;	β-catGOF/+	







Pituitary	 gland	 organogenesis	 is	 characterized	 by	 a	 series	 of	 discrete	 stages,	
beginning	with	 the	 induction	of	Rathke’s	pouch	and	culminating	 in	a	 fully-functioning,	









begins	 when	 lineage-specific	 transcription	 factors	 –	 POU1F1,	 TBX19,	 and	 SF1	 –	 are	
expressed	in	pituitary	parenchyma	[Fig.	5.1A].	These	transcription	factors	are	necessary	




organogenesis	when	 deleted	 or	 stimulated	 in	 early	 pituitary	 progenitors,	 prior	 to	 the	
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induction	 of	 the	 second	 stage	 of	 pituitary	 development	 at	 e11.5	 (15,16).	 In	 contrast,	
deleting	 or	 stimulating	 β-CATENIN	 during	 the	 third	 or	 fourth	 stages	 of	 pituitary	
development	has	no	observable	effect	on	the	developing	pituitary	gland.	What	is	not	yet	








	 Previous	 studies	 used	 the	 Pitx1-cre	 to	 conditionally	 delete	 β-CATENIN	 in	 early	
pituitary	progenitors	at	e9.5,	prior	to	Rathke’s	pouch	invagination	(15).	This	generated	
Pitx1-cre;	 β-catfx/fx	 mutant	 embryos	 that	 do	 not	 express	 POU1F1,	 GH,	 TSHβ,	 or	 PRL.	
Similarly,	 our	 results	 demonstrate	 that	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	 have	
reduced	expression	of	POU1F1,	GH,	and	TSHβ	[Fig.	5.1B].	Prolactin	expression	was	not	
determined	 for	Prop1-cre;	 β-catfx/fx	mutant	 embryos	because	PRL	 is	 not	 detectible	 via	
immunostaining	at	e18.5,	unlike	the	other	anterior	pituitary	hormones.	
	 In	 wild-type	 embryos,	 PROP1	 interacts	 with	 β-CATENIN	 to	 initiate	 POU1F1	
transcription	 [Fig.	 5.1A]	 (15).	 As	 there	 are	 still	 a	 number	 of	 POU1F1-positive	 cells	 in	
Prop1-cre;	 β-catfx/fx	 mutant	 embryos,	 despite	 a	 drastic	 decrease	 in	 β-CATENIN	
expression,	we	wanted	to	further	examine	these	POU1F1-positive	cells	to	determine	if	it	
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is	 possible	 to	 initiate	 POU1F1	 transcription	 in	 the	 absence	 of	 β-CATENIN.	 Double	
immunostaining	 for	 POU1F1	 and	 β-CATENIN	 at	 e14.5	 showed	 that	 the	 few	 POU1F1-
positive	 cells	 remaining	 are	 positive	 for	 β-CATENIN,	 confirming	 that	 β-CATENIN	 is	
required	to	initiate	POU1F1	transcription.		
The	 presence	 of	 β-CATENIN	 in	 Prop1-cre;	 β-catfx/fx	 cells	 could	 result	 from	 the	
persistence	of	 a	pool	of	β-CATENIN	protein	 in	 the	 cell,	 such	as	 at	 the	 cell	membrane,	
following	 the	 generation	 of	 the	 β-catenin	 null	 allele	 at	 e11.5	 (77).	 However,	 a	 more	
likely	 possibility	 is	 that	 in	 some	 Prop1-cre;	 β-catfx/fx	 mutant	 cells,	 the	 Prop1-cre	
transgene	is	not	transcribed	and	the	β-catenin	null	allele	is	not	generated.	Regardless	of	
the	mechanism,	 the	 presence	 of	 LEF1	 in	 a	 subset	 of	Prop1-cre;	 β-catfx/fx	mutant	 cells	
demonstrates	that	canonical	WNT	signaling	is	still	active	in	these	cells	and	also	implies	
that	β-CATENIN	must	be	available	to	promote	POU1F1	transcription.	In	cell	culture,	LEF1	
inhibits	 the	 transcription	 of	 a	 POU1F1	 reporter	 construct,	 and	 Lef1-/-	 mice	 have	 an	
increase	 in	the	POU1F1	 lineage	(15).	Additionally,	miRNA-26b	 inhibits	LEF1	expression,	
which	 results	 in	 an	 increase	 in	 POU1F1	 expression	 (82).	 However,	 our	 results	
demonstrate	 that	 in	 vivo,	 LEF1	 and	 POU1F1	 can	 be	 expressed	 simultaneously	 in	 the	
same	cell,	implying	that	LEF1	expression	does	not	preclude	POU1F1	expression.	
In	 wild-type	 embryos,	 the	 Prop1-cre	 sufficiently	 targets	 an	 eGFP	 reporter	
construct	 in	 the	Rosa	 locus	and	generates	membrane-bound	eGFP	 in	 all	 anterior	 lobe	
cells	 (9).	 For	 some	 reason,	 not	 all	 anterior	 lobe	 cells	 in	 Prop1-cre;	 β-catfx/fx	 mutant	
embryos	express	eGFP.	This	 result	 implies	 that	 these	cells	have	differentiated	without	
activating	 the	 Prop1-cre	 transgene.	 In	 support	 of	 this	 possibility,	 Ames	 dwarf	 mice,	
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which	are	homozygous	null	for	Prop1,	have	small	patches	of	cells	that	express	POU1F1	
and	 differentiate	 into	 the	 POU1F1	 lineage	 cell	 types	 (33).	 Therefore,	 it	 is	 possible	 for	
some	 pituitary	 progenitors	 to	 differentiate	 into	 the	 POU1F1	 lineage	 without	 ever	
activating	Prop1.	We	 think	 that	 this	 subset	of	 eGFP-negative,	 POU1F1-positive	 cells	 in	
Prop1-cre;	 β-catfx/fx	mutant	 embryos	 have	 not	 activated	 the	Prop1-cre	 transgene,	 and	
thus	not	generated	the	β-catenin	null	allele.	How	POU1F1	is	activated	in	the	absence	of	





as	 Prop1-cre;	 β-catfx/fx	 mutant	 embryos	 have	 an	 anterior	 lobe	 that	 is	morphologically	
similar	to	wild-type	embryos.	This	morphology	is	in	contrast	to	Prop1-/-	pituitaries,	which	
have	a	dysmorphic	pituitary	gland,	a	reduced	anterior	 lobe,	and	an	increase	in	 luminal	
epithelium,	 demonstrating	 that	 the	 progenitors	 in	 Prop1-/-	 pituitaries	 are	 unable	 to	
complete	an	epithelial-to-parenchymal	transition	(31).	Although	PROP1	and	β-CATENIN	
form	 a	 complex	 to	 promote	 POU1F1	 transcription,	 it	 appears	 that	 PROP1,	 but	 not	 β-
CATENIN,	is	required	to	promote	EPT.	
Similar	 to	previous	 results	 in	Pitx1-cre;	β-catfx/fx	mutant	embryos,	Prop1-cre;	β-
catfx/fx	mutant	embryos	have	a	significant	increase	in	TBX19	expression	[Fig.	5.1B]	(15).	
SF1	 expression	 was	 not	 altered	 in	 Pitx1-cre;	 β-catfx/fx	 mutant	 embryos,	 whereas	 we	
found	a	 small	 but	 significant	 increase	 in	 SF1	expression	 in	Prop1-cre;	 β-catfx/fx	mutant	
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embryos	 [Fig.	 5.1B].	 The	 difference	 in	 SF1	 expression	 between	 the	 two	 studies	 may	








can	 be	 generated	 from	 embryonic	 stem	 cells	 in	 vitro	 (83–85).	 The	 primary	 hormone	
produced	in	these	cultures	is	ACTH,	which	requires	TBX19	expression.	The	percentage	of	




promote	 the	 POU1F1	 lineage	 is	 unknown.	Multiple	WNT	 ligands	 are	 expressed	 in	 the	
pituitary	progenitors	of	Rathke’s	pouch,	 including	WNT4,	WNT5A,	WNT11,	and	WNT16	
(1,21).	 Of	 these	 WNTs,	 only	 WNT4	 has	 been	 shown	 to	 affect	 the	 differentiation	 of	
hormone	 cell	 types,	 as	Wnt4-/-	 embryos	 exhibit	 a	 decrease	 in	 the	 number	 of	 POU1F1	
lineage	 cells	 (21).	 What	 is	 not	 known,	 however,	 is	 whether	 WNT4	 is	 acting	 via	 a	
canonical	 or	 non-canonical	 pathway.	 As	 we	 know	 from	 previous	 studies,	 it	 is	 the	
combination	 of	 ligand	 and	 receptor	 that	 determines	 whether	 the	 WNT	 signaling	
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pathway	 that	 is	 activated	 is	 canonical	 or	 non-canonical	 (59–61).	 Further	 studies	 are	





the	 intermediate	 lobe	 instead	of	 the	usual	melanotropes,	 and	Hes1-/-	 embryos,	which	









mutant	 pituitaries	 at	 e14.5,	 the	 total	 number	 of	 cells	 in	 these	 pituitaries	 is	 not	
significantly	different	compared	to	wild-type	pituitaries.	This	suggests	that	a	regulatory	
mechanism	 exists	 through	 which	 the	 three	 cell	 specification	 pathways	 are	 kept	 in	
balance	 such	 that	 the	 loss	 of	 one	 pathway	 results	 in	 the	 channeling	 of	 more	 cells	
towards	the	other	two	pathways.	We	know	from	previous	studies	that	interfering	with	




positive	 and	 have	 not	 yet	 committed	 to	 one	 of	 the	 three	 cell	 specification	 pathways.	




	 Activating	 mutations	 in	 β-catenin	 have	 been	 shown	 to	 generate	 ACP	 tumors	
when	 stimulated	 in	 early	 pituitary	 progenitors,	 using	 the	 Hesx1-cre,	 and	 in	 adult	
pituitary	 stem	 cells,	 using	 the	 Sox2creERT2	 (16,43).	 We	 have	 shown	 that	 pituitary	
progenitors	 are	 still	 sensitive	 to	 canonical	WNT	 signaling	during	 EPT	 and	 that	 gain-of-
function	mutations	 in	β-catenin	at	this	stage	in	pituitary	development	also	result	 in	an	
ACP-like	 phenotype.	 This	 dysmorphology	 is	 characterized	 by	 a	 more	 than	 threefold	
increase	 in	 epithelial	 tissue	 in	 the	 developing	 pituitary	 gland	 along	 with	 the	
accumulation	of	β-CATENIN	in	foci	that	branch	off	from	the	luminal	epithelium.	The	first	
few	 foci	 that	 appear	 at	 e12.5	 are	 small	 and	 sparse,	 but	 they	 quickly	 expand	 to	 large	
clusters	of	cells	that	branch	off	from	the	luminal	epithelium	by	e14.5.		
Based	 on	 this	 large	 accumulation	 of	 periluminal	 epithelium,	 we	 believe	 that	
introducing	 a	 gain-of-function	 mutation	 in	 β-CATENIN	 at	 this	 stage	 inhibits	 the	 EPT	
necessary	for	anterior	lobe	formation.	In	support	of	this	theory,	the	cells	adjacent	to	the	
periluminal	epithelium	have	the	morphology	of	head	mesenchyme,	rather	than	that	of	
anterior	 lobe	 parenchyma.	 Additionally,	 SOX9	 is	 normally	 expressed	 weakly	 in	 the	
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luminal	 epithelium	 and	 strongly	 in	 the	 posterior	 lobe	 and	 head	 mesenchyme	






protein	 is	 unusual.	We	 know	 that	 PROP1	 is	 necessary	 for	 promoting	 EPT	 through	 the	
transcription	of	Zeb2,	Gli2,	Mmp2,	Mmp3,	and	Mmp16,	while	inhibiting	the	transcription	
of	 Cldn23	 (Claudin23)	 and	 CDH1	 (E-cadherin)	 (30).	 Notch2	 transcription	 is	 also	
stimulated	 by	 PROP1,	 and	 NOTCH	 signaling	 is	 known	 to	 promote	 EMT	 in	 cancer	 and	
development	(30,41).	Since	both	PROP1	and	NOTCH2	are	inhibited	by	the	high	levels	of	
β-CATENIN	 in	 Prop1-cre;	 β-catGOF	 mutant	 embryos,	 we	 think	 that	 the	 transcriptional	
profile	 necessary	 for	 EPT	 is	 not	 expressed	 in	 these	 embryos,	 thus	 preventing	 the	
formation	of	an	anterior	lobe.	
The	 production	 of	 the	β-catGOF	 protein	 in	 PROP1-positive	 pituitary	 progenitors	
prevents	the	differentiation	of	hormone	cell	types.	We	were	unable	to	detect	individual	
hormones	or	the	lineage	specific	markers	POU1F1,	TBX19,	and	SF1	in	Prop1-cre;	β-catGOF	
mutant	 pituitaries	 [Fig.	 5.1C].	 Additionally,	 the	 large	 cell	 clusters	 that	 expressed	 high	
levels	of	β-CATENIN	did	not	express	the	pituitary	progenitor	transcription	factors	SOX2,	
LHX3,	 and	 PROP1,	 and	 they	 had	 a	 decrease	 in	 SOX9	 expression.	 These	 results	
demonstrate	 that	 persistent	β-catGOF	 protein	 in	 pituitary	 progenitors	 shifts	 these	 cells	
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away	 from	 a	 pituitary	 identity.	 Similarly,	 ACP	 tumors	 do	 not	 produce	 pituitary	
hormones,	 but	 they	 can	 become	 calcified	 and	 produce	 the	 enamel	 proteins	
characteristic	 of	 teeth	 (13).	 This	 suggests	 that	 ACPs	 could	 represent	 a	 reversion	 of	
pituitary	progenitors	to	an	earlier,	more	oral	ectoderm-like	fate.		
CK8	and	CK18	were	previously	used	 to	 identify	Hesx1-cre;	β-catGOF/+	 tumors	 as	
having	 an	 epithelial	 phenotype,	 consistent	 with	 oral	 ectoderm	 (16).	 We	 used	 an	
antibody	that	recognizes	both	CK8	and	CK18	to	characterize	wild-type	and	Prop1-cre;	β-
catGOF	 mutant	 pituitaries.	 CK8/CK18	 are	 expressed	 throughout	 the	 intermediate	 and	
anterior	lobes	of	wild-type	pituitaries,	demonstrating	that	this	epithelial	marker	is	part	
of	a	normal	embryonic	pituitary	 identity.	 In	Prop1-cre;	β-catGOF	mutant	pituitaries,	 the	
regions	with	 high	 β-CATENIN	 expression	 did	 not	 express	 CK8/CK18,	 consistent	with	 a	
shift	 of	 these	 cells	 away	 from	 a	 normal	 pituitary	 identity.	 These	 cell	 clusters	 also	
expressed	SHH,	which	is	normally	expressed	in	the	oral	ectoderm	but	is	excluded	from	
the	 invaginating	Rathke’s	pouch	[Fig.	5.1C]	 (23).	 In	order	 to	confirm	that	Prop1-cre;	β-
catGOF	mutant	pituitaries	have	 reverted	 to	an	oral	 ectoderm	state,	 further	 studies	will	
need	to	be	completed	to	identify	markers	that	can	discriminate	between	embryonic	oral	
ectoderm	and	pituitary	progenitors	[Fig.	5.1C].	
Because	 our	 Prop1-cre;	 β-catGOF	 mutant	 pituitaries	 contain	 large	 foci	 which	
resemble	those	of	previous	gain-of-function	β-CATENIN	models	 that	have	been	shown	
to	correlate	with	human	ACP	tumors,	we	wanted	 to	determine	whether	 these	high	β-
CATENIN	 cell	 clusters	 possess	 similar	 features.	We	 know	 that	ACP	 tumors	 have	 a	 low	
mitotic	index,	so	we	used	Ki67	and	CCND2	as	proliferative	markers	in	the	Prop1-cre;	β-
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catGOF	 mutant	 pituitaries	 (14).	 Ki67	 is	 primarily	 restricted	 to	 the	 epithelial	 regions	
outside	the	high	β-CATENIN	cell	clusters,	demonstrating	that	these	cells	are	not	actively	
cycling.	CCND2	is	also	expressed	in	actively	cycling	cells	and	is	a	target	of	canonical	WNT	
signaling	 (63).	 In	 large,	 high	β-CATENIN	 cell	 clusters,	 CCND2	expression	 is	 significantly	
reduced,	confirming	that	these	epithelial	regions	are	not	actively	cycling.	This	decreased	
expression	 of	 CCND2	 in	 the	 large	 clusters	 of	 cells	 with	 high	 β-CATENIN	 expression	 is	
contrary	 to	 the	expected	 stimulation	of	CCND2	by	 canonical	WNT	 signaling.	However,	
CCND2	 is	 expressed	 at	 higher	 levels	 in	 smaller	 cell	 clusters	 with	 high	 β-CATENIN	
expression,	 which	 is	 consistent	 with	 its	 role	 as	 a	 target	 of	 canonical	 WNT	 signaling.	




still	present	at	 the	cell	membrane	 [Fig.	4.1I].	 Increased	 levels	of	β-CATENIN	generated	









the	 molecular	 characterization	 of	 human	 ACP,	 have	 determined	 that	 congenital	 and	
adult-onset	 ACP	 are	 caused	 by	 gain-of-function	 mutations	 in	 β-catenin	 that	 occur	 in	
pituitary	progenitors	during	embryogenesis	or	in	adult	pituitary	stem	cells,	respectively	
(56).	These	ACP	tumors	are	formed	in	a	paracrine	manner,	wherein	a	cell	cluster	with	an	
activating	 mutation	 in	 β-catenin	 signals	 to	 adjacent	 cells,	 which	 then	 proliferate	 and	
expand	to	form	the	mass	of	the	tumor	(43).	Thus,	the	generation	of	ACP	relies	on	a	cell	
cluster	with	high	β-CATENIN	expression	 interacting	with	the	normal	anterior	 lobe	cells	
that	 surround	 it	 via	 paracrine	 signals.	 Our	mouse	model,	Prop1-cre;	 β-catGOF/+,	 differs	
from	these	other	mouse	models	in	that	a	normal	pituitary	anterior	lobe	is	never	formed	
and	the	dysmorphic	tissue	that	remains	consists	of	periluminal	epithelium	with	high	β-
CATENIN	expression.	The	earlier	onset	of	 the	Hesx1-cre	 vs.	 the	Prop1-cre	 likely	causes	
the	difference	in	phenotypes.	Perhaps	early	pituitary	progenitors,	which	express	HESX1,	
can	 inhibit	 transcription	from	the	β-catenin	 locus,	which	prevents	the	accumulation	of	
activated	β-CATENIN	 in	some	cells,	allowing	 for	anterior	 lobe	 formation.	Children	with	
activating	mutations	in	β-catenin	that	mimic	the	onset	of	the	Prop1-cre;	β-catGOF	would	
present	with	a	complete	pituitary	hormone	deficiency	at	birth.	The	morphology	of	the	
pituitary	 gland	 would	 likely	 resemble	 the	 initially	 enlarged	 pituitary	 gland	 of	 Prop1-/-	
CPHD	patients,	where	the	pituitary	progenitors	fail	to	undergo	EPT	and	thus	do	not	form	
an	anterior	lobe	(31,86).	




it	 must	 also	 be	 carefully	 regulated	 in	 order	 to	 ensure	 the	 progression	 of	 pituitary	
progenitors	through	EPT.	Additionally,	our	results	support	previous	studies	by	providing	
further	 evidence	 towards	 the	 idea	 that	 pituitary	 progenitors	 can	 undergo	 a	 cell	 fate	
switch	 so	 as	 to	maintain	 balance	when	 one	 cell	 specification	 pathway	 is	 inhibited.	 In	
order	to	confirm	this	hypothesis,	future	studies	will	need	to	determine	how	the	process	
of	 cell	 specification	 is	 regulated	 in	 the	 pituitary	 gland	 and	 how	 interfering	 with	 this	
process	 affects	 the	 regulation	of	pituitary	progenitors.	 This	 study	also	provides	a	new	
model	of	ACP	that	exhibits	a	different	morphology	compared	to	previous	models,	one	in	
which	pituitary	progenitors	 cannot	undergo	EPT	or	 form	an	anterior	 lobe	and	 thus	do	
not	express	markers	of	 terminal	differentiation.	The	molecular	characterization	of	 this	
new	 model	 could	 be	 very	 useful	 in	 the	 diagnosis	 of	 patients	 which	 have	 activating	
mutations	 in	 β-catenin	 but	 which	 do	 not	 exhibit	 the	 same	 pituitary	 morphology	 and	
secondary	characteristics	of	previously	identified	cases	of	ACP.	Together,	the	results	of	
this	 study	 show	 that	 pituitary	 progenitors	 are	 highly	 sensitive	 to	 external	 regulation	
prior	to	the	point	in	which	they	commit	to	a	specific	cell	fate,	and	that	interfering	with	
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